 SOUTH SAN FRANCISCO, Calif., Nov. 30, 2022 GLOBE NEWSWIRE -- RAPT Therapeutics, Inc. Nasdaq: RAPT RAPT or the Company, a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that its abstract from its ongoing Phase 12 study of FLX475 as monotherapy and in combination with pembrolizumab in cancer patients has been accepted for poster presentation at the European Society for Medical Oncology ESMO Immuno-Oncology Annual Congress taking place December 7-9, 2022 in Geneva, Switzerland. The presentation will include data from checkpoint inhibitor-naïve NSCLC patients treated with the combination of FLX475 plus pembrolizumab including their PD-L1 status, and patients with EBV-positive NKT cell lymphoma treated with FLX475 monotherapy. 